Skeletal Radiology

, Volume 41, Issue 4, pp 409–414

Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response

  • Yoshiko Yamashita
  • Takatoshi Aoki
  • Takeshi Hanagiri
  • Chiharu Yoshii
  • Hiroshi Mukae
  • Hidetaka Uramoto
  • Yukunori Korogi
Scientific Article

Abstract

Objective

To assess the frequency of osteosclerotic changes on CT that appeared after treatment with gefitinib in patients with lung adenocarcinoma and the relationship between the osteosclerotic changes and the response to the therapy.

Materials and methods

Our study included 41 patients with lung adenocarcinoma who underwent chest CT both before (CTpre) and after (CTpost) starting treatment with gefitinib. The presence or absence of bone metastases was assessed on the CTpre, and the interval bony change after the therapy was classified as lytic, sclerotic, or no changes on the CTpost. The relationship between treatment results of primary lung cancer and interval bony changes was evaluated.

Results

Osteosclerotic lesions were identified in 11 patients (27%) on CTpost; in 6 of 11 patients osteosclerotic lesions newly appeared where the CTpre showed no bone metastasis before the gefitinib therapy. There were significant differences in the therapeutic response of the primary cancers (P < 0.001) and in the survival rate (P < 0.01) in patients with osteosclerotic changes versus those without osteosclerotic changes.

Conclusion

Osteosclerotic changes on CT, observed after gefitinib treatment in patients with lung adenocarcinomas, may be an indicator of a good therapeutic response.

Keywords

Bone Lung cancer CT Gefitinib Metastasis 

References

  1. 1.
    Pao W, Zakowski M, Cordon-Cardo C, et al. Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib. Proc Am Soc Clin Oncol 2004; 23: 623 s (abstract).Google Scholar
  2. 2.
    Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237–46.PubMedCrossRefGoogle Scholar
  3. 3.
    Normanno N, De Luca A, Aldinucci D, et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer. 2005;12:471–82.PubMedCrossRefGoogle Scholar
  4. 4.
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588–94.PubMedCrossRefGoogle Scholar
  6. 6.
    Zampa G, Zampa G, Moscato M, Brannigan BW, Morabito A, Bell DW, et al. Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. Lung Cancer. 2008;60:452–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Satoh H, Ishikawa H, Ohara G, Kikuchi N, Sekizawa K. Prolonged response to gefitinib in bone metastasis. Med Oncol. 2009;26:102–2.Google Scholar
  8. 8.
    Okano Y, Nishio M. Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis. Clin Calcium. 2008;18:527–33.PubMedGoogle Scholar
  9. 9.
    Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastasis in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996;14:2552–9.PubMedGoogle Scholar
  10. 10.
    Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastasis in patients with breast cancer. A dose-seeking study. Cancer. 1994;74:2949–55.PubMedCrossRefGoogle Scholar
  11. 11.
    Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335:1785–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol. 2001;19:3562–71.PubMedGoogle Scholar
  13. 13.
    Normanno N, Gullick WJ. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr Relat Cancer. 2006;13:3–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Dawar AL, Farrugia AN, Condina MR, et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood. 2006;107:4334–7.CrossRefGoogle Scholar
  15. 15.
    Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354:2006–2013.PubMedCrossRefGoogle Scholar
  16. 16.
    Chao HS, Chang CP, Chiu CH, et al. Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib. Clin Nucl Med. 2009;34:346–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Yamaguchi T. Intertrabecular vertebral metastases: metastases only detectable on MR imaging. Semin Musculoskelet Radiol. 2001;5:171–5.PubMedCrossRefGoogle Scholar

Copyright information

© ISS 2011

Authors and Affiliations

  • Yoshiko Yamashita
    • 1
  • Takatoshi Aoki
    • 1
  • Takeshi Hanagiri
    • 2
  • Chiharu Yoshii
    • 3
  • Hiroshi Mukae
    • 3
  • Hidetaka Uramoto
    • 2
  • Yukunori Korogi
    • 1
  1. 1.Department of RadiologyUniversity of Occupational and Environmental Health, School of MedicineKitakyushuJapan
  2. 2.Second Department of SurgeryUniversity of Occupational and Environmental Health, School of MedicineKitakyushuJapan
  3. 3.Department of Respiratory DiseaseUniversity of Occupational and Environmental Health, School of MedicineKitakyushuJapan

Personalised recommendations